Royalty Pharma Announces $761 Million Acquisition of Interest in BG-12 and Fumaderm
Purchase of Interest in Fumapharm Earn-Out Represents Interest in BG-12 and Fumaderm. New York, NY (US) – May 2, 2012 — Royalty Pharma announced today that it had acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash.